Financial News · Live Terminal

Page 143 of 321

Canaccord Genuity Downgrades ZoomInfo to Hold From Buy, Adjusts Price Target to $5 From $12

ZoomInfo (GTM) has an average rating of hold and mean price target of $6.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Financial News · Live Terminal

Canaccord Genuity Downgrades ZoomInfo to Hold From Buy, Adjusts Price Target to $5 From $12

Benchmark Initiates Tandem Diabetes Care at Hold

Piper Sandler Downgrades ZoomInfo to Underweight From Neutral, Adjusts Price Target to $4 From $7

Rosenblatt Securities Downgrades Emerald to Neutral From Buy, Adjusts PT to $5.03 From $7.70

Raymond James Downgrades Gitlab to Market Perform From Outperform

Stifel Downgrades United Parks & Resorts to Hold From Buy, Adjusts Price Target to $40 From $43

Rothschild & Co Redburn Downgrades Toast to Neutral From Buy, Adjusts Price Target to $35 From $47

Jefferies Downgrades Accuray to Hold From Buy, Adjusts Price Target to $0.35 From $3.50

BofA Upgrades Bentley Systems to Buy From Neutral, Price Target is $40

Piper Sandler Downgrades LENZ Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $39

JPMorgan Initiates Alamar Biosciences at Overweight With $30 Price Target

TD Cowen Initiates Alamar Biosciences at Buy With $30 Price Target

Leerink Initiates Alamar Biosciences at Outperform With $35 Price Target

Stifel Initiates Alamar Biosciences at Buy With $28 Price Target

Jefferies Initiates AEVEX Corp at Buy With $32 Price Target

Baird Initiates AEVEX Corp at Outperform With $38 Price Target

JPMorgan Initiates AEVEX Corp at Overweight With $33 Price Target

Goldman Sachs Initiates AEVEX Corp at Buy With $34 Price Target

Raymond James Initiates AEVEX Corp at Outperform With $35 Price Target

William Blair Initiates AEVEX Corp at Outperform

Canaccord Genuity Downgrades ZoomInfo to Hold From Buy, Adjusts Price Target to $5 From $12

Benchmark Initiates Tandem Diabetes Care at Hold

Piper Sandler Downgrades ZoomInfo to Underweight From Neutral, Adjusts Price Target to $4 From $7

Rosenblatt Securities Downgrades Emerald to Neutral From Buy, Adjusts PT to $5.03 From $7.70

Raymond James Downgrades Gitlab to Market Perform From Outperform

Stifel Downgrades United Parks & Resorts to Hold From Buy, Adjusts Price Target to $40 From $43

Rothschild & Co Redburn Downgrades Toast to Neutral From Buy, Adjusts Price Target to $35 From $47

Jefferies Downgrades Accuray to Hold From Buy, Adjusts Price Target to $0.35 From $3.50

BofA Upgrades Bentley Systems to Buy From Neutral, Price Target is $40

Piper Sandler Downgrades LENZ Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $39

JPMorgan Initiates Alamar Biosciences at Overweight With $30 Price Target

TD Cowen Initiates Alamar Biosciences at Buy With $30 Price Target

Leerink Initiates Alamar Biosciences at Outperform With $35 Price Target

Stifel Initiates Alamar Biosciences at Buy With $28 Price Target

Jefferies Initiates AEVEX Corp at Buy With $32 Price Target

Baird Initiates AEVEX Corp at Outperform With $38 Price Target

JPMorgan Initiates AEVEX Corp at Overweight With $33 Price Target

Goldman Sachs Initiates AEVEX Corp at Buy With $34 Price Target

Raymond James Initiates AEVEX Corp at Outperform With $35 Price Target

William Blair Initiates AEVEX Corp at Outperform